Please login to the form below

Not currently logged in
Email:
Password:

CAR-T therapy

This page shows the latest CAR-T therapy news and features for those working in and with pharma, biotech and healthcare.

Gracell reports impressive data with one-day CAR-T for leukaemia

Gracell reports impressive data with one-day CAR-T for leukaemia

The testing phase still applies with  Gracell’s approach of course, but that means the CAR-T therapy can be prepared in as little as eight days, whereas Kymriah needs a ... The biotech thinks that its express approach to production will also reduce

Latest news

  • Novartis’ CAR-T Kymriah scores SMC approval Novartis’ CAR-T Kymriah scores SMC approval

    The SMC approved the CAR-T therapy for use in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who have not responded to two or more prior ... Gilead faced an  initial hurdle when initially NICE rejected the use of its

  • Celgene boosts IO presence with Immatics deal Celgene boosts IO presence with Immatics deal

    CAR-T cell therapies, the most clinically established form of ACT, can recognise only the specific antigens on the surface of cancer cells. ... The deal adds to Celgene existing presence in cell therapy - it is working with  Bluebird Bio, on CAR-T

  • GSK preps filings for BCMA-targeting multiple myeloma drug GSK preps filings for BCMA-targeting multiple myeloma drug

    GSK2857916 is one of a slew of BCMA-targeting therapies coming through the biopharma industry pipeline, jostling for position with a CAR-T therapy from Celgene and Bluebird Bio called bb2121 ... That suggests GSK is going for highly-refractory patients

  • Triplet approvals for myeloma boost Celgene in Q2 Triplet approvals for myeloma boost Celgene in Q2

    of triplet therapy which resulted in “increases in treatment duration and market share.” It was a similar story for Pomalyst/Imnovid (pomalidomide), up 22% to $619m, according to the company. ... CAR-T therapy liso-cel (lisocabtagene maraleucel)

  • Gilead strikes $5.1bn deal to bolster ties with Galapagos Gilead strikes $5.1bn deal to bolster ties with Galapagos

    CAR-T therapy for cancer Yescarta (axicabtagene ciloleucel) – acquired as part of its $12bn takeover of Kite – has been slow to build sales, bringing in $264m last year. ... Meanwhile, Gilead has had a couple of failed trials with its lead

More from news
Approximately 8 fully matching, plus 77 partially matching documents found.

Latest Intelligence

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to ... This is demonstrated in Gilead securing two truly groundbreaking partnerships

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    This is informed by the experience of CAR-T cell therapies, where Novartis’ Kymriah – the first ever CAR-T approved in 2017 – looks set to remain a loss-leader for many ... Its most important pipeline candidate, however, is the multiple myeloma

  • Cell and gene therapy Cell and gene therapy

    In addition, as Eric Althoff from Swiss pharmaceutical firm Novartis points out, making a patient-specific product like a CAR-T therapy is very different from producing a volume drug. ... In the case of a personalised therapy like CAR-T, the cost of the

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The follow-up, Ultomiris ALXN1210, is a second-generation PNH

  • Deal Watch October 2018

    radioligands and CAR‐T for cancer. $2.1B. Sale. Aurobindo. NovartIs sold part of Sandoz’s US generics. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.

More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • The impossible launch

    SpaceX is inspiring people in a way that NASA hasn’t managed in over 30 years. ... Today’s therapy advances, such as CAR-T and gene therapy, are just as exciting and will help shape our world in the years to come.

  • Precision paediatrics: Treating patients with CAR-T

    Here, we discuss the story behind CAR-T therapy and the steps being taken to ensure more patients can access it. ... It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach.

  • Highlights in haematologic malignancy from ASH 2018

    The spotlight shone on Chimeric Antigen Receptor(CAR) T-cell therapy; a transformative approach where the patient’s T cells are harvested and re-engineered to recognise antigens expressed by the ... A reduced risk of relapse was also seen when

  • Training the next generation of biotech leaders

    In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.

  • Innovation in pharma: the highs and lows of the current healthcare economy

    Gene therapies often require a ‘one-time only’ treatment offering life-changing potential to patients with conditions where currently there may be no available therapy at all, for instance, in rare ... Also in cancers: chimeric antigen receptor T

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics